Is Daklinza discontinued?

— Previously, the FDA announced the discontinuation of Daklinza 90 mg tablets with planned distribution ceasing in December 2018. — Bristol Myers Squibb has planned to cease distribution for Daklinza 30 mg and 60 mg tablets in June 2019. — All Daklinza tablets are now discontinued.

What is Daklinza used for?

Daklinza (daclatasvir) is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body. Daklinza is used in combination with other medications to treat chronic hepatitis C in adults.

Why was daclatasvir discontinued?

The FDA issued a complete response letter for NS5A inhibitor daclatasvir saying it was unable to approve the drug because the marketing application was for its use in tandem with asunaprevir, an NS3/NS4A protease inhibitor discontinued in the US by BMS last month for commercial reasons.

Is Olysio discontinued?

optumrx.com — The discontinuation was not due to any safety, efficacy or quality issues. — Moreover, Janssen will voluntary withdraw the New Drug Application for Olysio in the U.S. and product will no longer be available, effective May 25, 2018.

Where can I get more information about Daklinza?

From this website you will be able to access information about Daklinza. The information contained in this website is meant exclusively for international Healthcare Professionals and not for members of the general public.

How is Daklinza used to treat hepatitis C?

DAKLINZA is a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir, with or without ribavirin, the treatment of chronic HCV for genotype 1 or 3 infection.

When to use Daklinza with sofosbuvir and ribavirin?

DAKLINZA is indicated for use with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection [seeDOSAGE AND ADMINISTRATIONand Clinical Studies]. Limitations Of Use

What are the ingredients in Daklinza 30 mg tablets?

DAKLINZA 30 mg tablets contain 30 mg daclatasvir (equivalent to 33 mg daclatasvir dihydrochloride) and the inactive ingredients anhydrous lactose (58 mg), microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate, and Opadry green.